Skip to main content

Table 3 Therapy outcomes of the study population

From: Retrospective study of Dana Farber Consortium Protocol in newly diagnosed Egyptian adolescents and young adults with acute lymphoblastic leukemia: Tanta experience

Variables

Number (%)

Response

Complete remission (CR)

38 (92.68%)

Refractory

3 (7.32%)

Relapse

Relapse

11 (26.83%)

Non-relapse

30 (73.17%)

Survival

Living

31 (75.61%)

Dead

10 (24.39%)